A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Roxadustat (Primary) ; Darbepoetin alfa; Darbepoetin alfa
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms Dolomites
- Sponsors Astellas Pharma Europe Ltd
- 05 Dec 2019 Status changed from active, no longer recruiting to completed.
- 05 Dec 2019 This trial has been completed in Spain (Global End Date: 6 Nov 2019), according to European Clinical Trials Database record.
- 24 Sep 2019 This trial has been completed in Portugal, according to European Clinical Trials Database record.